CRF receptor antagonists and methods relating thereto

US5795905A · kind A · utility

Assignee

• Neurocrine Biosciences, Inc. · US

Inventors

• James R. McCarthy · Dorpsstraat, US
• Yun Feng Xie · Carlsbad, US
• Jeffrey P. Whitten · San Diego, US
• Thomas R. Webb · Olivenhain, US
• Chen Chen · San Diego, US
• John Ramphal · Union City, US

Key dates

• Filing date: Jun 6, 1995
• Grant date: Aug 18, 1998
• Expiry date: Jun 6, 2015

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D285/08
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

CRF receptor antagonists are disclosed. Such receptor antagonists are thiadiazole-, pyrimidine-, triazine-, and triazole-containing compounds substituted with both a C3-C14 monocyclic or fused, homoaryl or heteroaryl group and a substituted amine group. The CFR receptor antagonists have utility in the treatment of a variety of disorders, including disorders associated with the hypersecretion of CRF.